drugset / Trial / NCT01910311

A Study of Baricitinib and Rifampicin in Healthy Participants

NCT01910311

Phase 1 Completed 18 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purposes of this study are to look at what effect multiple doses of rifampicin have on a single dose of baricitinib and to look at the safety and tolerability of these drugs. Side effects will be documented. The study will last approximately 31 days from the first dose to the end of the study.

Timeline

Start
2013-08
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Baricitinib Small molecule 10 mg Oral
Subject Rifampin Small molecule 600 mg Oral

Indications

No indication recorded.